Viking Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121
Mailing Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121
Phone
858-704-4660
Fiscal Year End
1231
EIN
461073877
Financial Overview
FY2025
$908.32M
Total Assets
$880.28M
Stockholders' Equity
$-0.91
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 1, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 10-K Annual financial report | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 3 Initial insider ownership report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
Annual Reports
10-K
February 11, 2026
- Positive top-line results from Phase 2b VOYAGE study for VK2809 in NASH, demonstrating significant reductions in liver fat.
- Initiated Phase 2 VENTURE study for VK2735 in obesity, a critical step for this promising dual agonist.
Insider Trading
STRONG SELL
5 insiders
14 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.